Jun 3 |
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
|
Jun 3 |
Eli Lilly granted exclusive license to QurAlis candidate for neurodegenerative diseases
|
Jun 3 |
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
|
Jun 3 |
The Zacks Analyst Blog Highlights Eli Lilly, T-Mobile US, BHP, American International and Exelon
|
Jun 3 |
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
|
Jun 3 |
Eli Lilly adds ALS drug prospect with QurAlis deal
|
Jun 2 |
SA Asks: Which weight-loss stocks should investors be watching?
|
Jun 2 |
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
|
Jun 1 |
Eli Lilly's Growth And Challenges: A Cautious Buy
|
Jun 1 |
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
|